Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Erlotinib [cytosol]

Class:IdChemicalDrug:1173285
_displayNameErlotinib [cytosol]
_timestamp2018-12-12 00:29:46
compartment[Compartment:70101] cytosol
created[InstanceEdit:1173286] Orlic-Milacic, Marija, 2011-01-24
crossReference[DatabaseIdentifier:9628096] ChEBI:114785
disease[Disease:1500689] cancer
literatureReference[LiteratureReference:1181184] Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
[LiteratureReference:1181191] Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
modified[InstanceEdit:1181158] Orlic-Milacic, Marija, 2011-01-28
[InstanceEdit:1181170] Orlic-Milacic, Marija, 2011-01-28
[InstanceEdit:1181197] Orlic-Milacic, Marija, 2011-01-28
[InstanceEdit:1217487] Orlic-Milacic, Marija, 2011-02-16
[InstanceEdit:1220593] Orlic-Milacic, Marija, 2011-02-22
[InstanceEdit:1667319] Orlic-Milacic, Marija, 2011-10-14
[InstanceEdit:9016686] Orlic-Milacic, Marija, 2017-08-14
[InstanceEdit:9028147] Weiser, JD
[InstanceEdit:9616752] Shorser, Solomon, 2018-08-13
[InstanceEdit:9619953] Wu, G, 2018-09-19
[InstanceEdit:9627975] Wu, G, 2018-11-05
[InstanceEdit:9631716] Wu, G, 2018-12-12
nameErlotinib
Tarceva
OSI-774
Reversible tyrosine kinase inhibitor erlotinib EGFR specific
referenceEntity[ReferenceTherapeutic:9016669] erlotinib [Guide to Pharmacology:4920]
stableIdentifier[StableIdentifier:2017814] R-ALL-1173285.2
summation[Summation:1181195] Erlotinib (OSI-774, Tarceva) is an EGFR-specific tyrosine ki...
(hasMember)[DefinedSet:1176053] Reversible EGFR-specific TKIs [cytosol]
[Change default viewing format]
No pathways have been reviewed or authored by Erlotinib [cytosol] (1173285)
Follow Reactome